These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 30393090)

  • 21. The role of dental care providers in the management of patients prescribed bisphosphonates: brief clinical guidance.
    Abed HH; Al-Sahafi EN
    Gen Dent; 2018; 66(3):18-24. PubMed ID: 29714695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
    Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
    J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
    Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Bisphosphonate-related osteonecrosis of the jaw].
    Atanes-Bonome P; Atanes-Bonome A; Ríos-Lage P; Atanes-Sandoval AD
    Semergen; 2014 Apr; 40(3):143-8. PubMed ID: 24001573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw.
    Yarom N; Van Poznak CH; Epstein JB; Ottaviani G; Matsuda Y; Migliorati C; Elad S
    Support Care Cancer; 2024 Jul; 32(8):547. PubMed ID: 39048887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
    Fusco V; Campisi G; Bedogni A
    Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiresorptive treatment-associated ONJ.
    Eleutherakis-Papaiakovou E; Bamias A
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 29063702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.
    Matsumoto A; Sasaki M; Schmelzeisen R; Oyama Y; Mori Y; Voss PJ
    Clin Oral Investig; 2017 Jan; 21(1):127-134. PubMed ID: 26924135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients.
    Jung S; Kim J; Park JH; Kim KY; Kim HJ; Park W
    Sci Rep; 2022 May; 12(1):8641. PubMed ID: 35606457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis.
    Campisi G; Mauceri R; Bertoldo F; Fusco V; Bedogni A
    Head Face Med; 2021 Jul; 17(1):25. PubMed ID: 34243807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England.
    Sturrock A; Preshaw PM; Hayes C; Wilkes S
    BMJ Open; 2019 Mar; 9(3):e024376. PubMed ID: 30833319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-induced osteonecrosis of the jaw: the state of the art.
    Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D
    Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention.
    Di Fede O; Panzarella V; Mauceri R; Fusco V; Bedogni A; Lo Muzio L; Sipmo Onj Board ; Campisi G
    Biomed Res Int; 2018; 2018():2684924. PubMed ID: 30306086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw.
    Kim HY
    Endocrinol Metab (Seoul); 2021 Oct; 36(5):917-927. PubMed ID: 34674506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2.
    Coropciuc RG; Grisar K; Aerden T; Schol M; Schoenaers J; Politis C
    Br J Oral Maxillofac Surg; 2017 Oct; 55(8):787-792. PubMed ID: 28760314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.
    Hallmer F; Bjarnadottir O; Götrick B; Malmström P; Andersson G
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Sep; 130(3):252-257. PubMed ID: 32536575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medication-related osteonecrosis of the jaw: A literature review and update.
    Kuroshima S; Al-Omari FA; Sasaki M; Sawase T
    Genesis; 2022 Sep; 60(8-9):e23500. PubMed ID: 36106755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.